Increasing prevalence of HIV-1 reverse transcriptase mutation K65R correlates with tenofovir utilization

Antiviral Therapy

Volumn 9, Issue 5, 2004, Pages 827-828

  Kagan, Ron M ^a   Merigan, Thomas C ^b   Winters, Mark A ^b   Heseltine, Peter N R ^a  

^a QUEST DIAGNOSTICS NICHOLS INSTITUTE   (United States)

^b STANFORD UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; LAMIVUDINE; RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR; RNA DIRECTED DNA POLYMERASE K65R; TENOFOVIR; UNCLASSIFIED DRUG;

CORRELATION COEFFICIENT; DRUG UTILIZATION; GENE MUTATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN IMMUNODEFICIENCY VIRUS PREVALENCE; LETTER; PREDICTION; PRIORITY JOURNAL; STATISTICAL ANALYSIS; VIRUS MUTATION; VIRUS RESISTANCE;

ADENINE; ANTI-HIV AGENTS; DRUG RESISTANCE, VIRAL; HIV INFECTIONS; HIV-1; HIV-1 REVERSE TRANSCRIPTASE; HUMANS; MUTATION; PHOSPHONIC ACIDS; PREVALENCE; REVERSE TRANSCRIPTASE INHIBITORS;

EID: 7244239503     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Letter

References (5)

1. Srinivas RV & Fridland A. Antiviral activities of 9-R-2-phosphonomethoxypropyl adenine (PMPA) and bis(isopropyloxymethylcarbonyl) PMPA against various drug-resistant human immunodeficiency virus strains. Antimicrobial Agents & Chemotherapy 1998, 42:1484-1487.
2. Wainberg MA, Miller MD, Quan Y, Salomon H, Mulato AS, Lamy PD, Margot NA, Anton KE & Cherrington JM. In vitro selection and characterization of HIV-1 with reduced susceptibility to PMPA. Antiviral Therapy 1999, 4:87-94.
3. Garcia-Lerma JG, Gerrish PJ, Wright AC, Qari SH & Heneine W. Evidence of a role for the Q151L mutation and the viral background in development of multiple dideoxynucleoside-resistant human immunodeficiency virus type 1. Journal of Virology 2000, 74:9339-9346.
4. Farthing C, Khanou H & Yeh V. Early virologic failure in a pilot study evaluating the efficacy of abacavir, lamivudine and tenofovir in the treatment naive HIV-infected patients. 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment. 13-16 July 2003, Paris, France. Abstract 43.
5. Gallant JE, Rodriguez AE, Weinberg W, Young B, Berger D, Lim ML, Liao Q, Ross L, Johnson J & Shaefer MS. Early non-response to tenofovir DF (TDF) + abacavir (ABC) and lamivudine (3TC) in a randomized trial compared to efavirenz (EFV) + ABC and 3TC: ESS30009 unplanned interim analysis. 43rd Interscience Conference on Antimicrobial Agents & Chemotherapy. 14-17 September 2003, Chicago, Ill., USA. Abstract H-1722a.